
Pharma Contract Risk Analyzer
Analyze pharma contracts for pricing risks and negotiation leverage in minutes
What You Can Do
You systematically evaluate incoming pharmaceutical contracts—from payers, healthcare systems, pharmacy chains, and specialty distributors—to surface pricing vulnerabilities, market access constraints, and negotiation leverage points before signing. Using a four-layer assessment model covering structural, access, compliance, and commercial risks, you transform 2–4 hours of manual contract review into a 20–30 minute structured analysis that protects margin and builds evidence-based negotiation strategies.
Features
Analyzes pricing formulas, indexing mechanisms, volume commitments, and rebate calculation structures to identify financial exposure
Maps formulary placement conditions, exclusion clauses, prior authorization requirements, and access barriers affecting product uptake
Flags reporting, audit rights, data submission requirements, and regulatory obligations embedded in contract terms
Evaluates term length, termination clauses, exclusivity provisions, and competitive constraints that affect market flexibility
Surfaces leverage points, missing protections, and renegotiation windows tailored to your competitive position
Enables rapid side-by-side risk assessment across multiple similar agreements (e.g., three Medicaid MCO deals)
Translates qualitative contract language into financial and market access impact estimates for stakeholder decision-making
Produces executive summaries, risk dashboards, and negotiation briefs ready for internal stakeholder review
Example Output
Input: Medicaid MCO contract with new rebate indexing clause and exclusivity provision
Risk Summary Output:
- Structural Risk (High): Dynamic rebate indexing to competitor pricing creates margin compression of 2–4% annually; no floor protection included
- Access Risk (Medium): Formulary placement contingent on prior authorization compliance; specialty tier placement reduces patient access vs. competitor products
- Compliance Risk (Medium): Monthly rebate reconciliation and quarterly audit rights require enhanced data systems; 30-day claims correction window unusually short
- Commercial Risk (High): 3-year exclusivity clause with automatic renewal prevents competitive repositioning; termination requires 180-day notice
Negotiation Levers Identified:
- Propose rebate floor tied to baseline volume; remove competitor-price indexing
- Request expedited formulary review pathway (60-day vs. 120-day standard)
- Negotiate 60-day termination window for contract Year 2+
- Clarify claims correction timeline and reduce audit frequency to semi-annual
Financial Impact Estimate: Current terms create $1.2M–$1.8M margin risk over contract term if rebate indexing fully activates
What's Included
- SKILL.md instruction file: Complete four-layer risk assessment framework and usage protocols
- Contract Risk Assessment Template: Structured worksheet covering structural, access, compliance, and commercial risk dimensions
- Risk Scoring Rubric: Quantified risk rating system (High/Medium/Low) with financial impact thresholds
- Negotiation Leverage Checklist: Pre-built list of common contract vulnerabilities and counter-proposal options
- Executive Summary Brief Template: One-page format for presenting findings to commercial, legal, and executive stakeholders
Who It's For
- Pricing & Market Access Analysts — Rapidly assess incoming payer and distributor contracts to identify negotiation strategy
- Commercial Contracting Managers — Evaluate terms before signature and flag risks requiring executive or legal escalation
- Pharma Sales Leaders — Understand payer agreement implications on pricing flexibility, market access, and competitive positioning
- Compliance & Audit Teams — Identify reporting and audit obligations embedded in contracts affecting operational readiness
- Business Development Professionals — Evaluate partnership, licensing, and distribution agreements for long-term risk
Best For
- Payer contract risk assessment (Medicaid, Medicare, commercial health plans, pharmacy benefit managers)
- Hospital system and integrated delivery network (IDN) group purchasing agreement (GPA) evaluation
- Specialty distributor and pharmacy chain contract renegotiation analysis
- Contract renewal and amendment cycle preparation with evidence-based counter-proposal development
- Competitive contract comparison across similar segments or geographies







